Recommendations for addressing mental health among pain management fellows during the COVID-19 pandemic.
The FDA has announced that it is requiring drug manufacturers for all opioid pain relievers and medicines to treat opioid use disorder to include new recommendations about naloxone to the prescribing information.
A team of investigators assessed clinical outcomes among patients with COVID-19 receiving ibuprofen for fever reduction.
Serum allopregnanolone levels are lower in women with either menstrually related or postmenopausal migraine compared with women without headache.
The permanent birth control device Essure is associated with higher rates of chronic lower abdominal or pelvic pain and abnormal uterine bleeding compared with tubal ligation.
Right-sided flank pain has been present for several months and occurs when standing, bending, and lifting—pain only improves when laying down.
Approximately one-third of patients with migraine reported using opioids to treat their symptoms, a practice that contrasts with current guidelines.
Galcanezumab was found to significantly improve work productivity and reduce interictal burden in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.
The bidirectional relationship between migraine and sleep disorders are examined in this article.
Positive results were announced from the phase 3 STOP-301 study evaluating INP104 (intranasal dihydroergotamine mesylate; Impel NeuroPharma) for the treatment of acute migraine in adults.
The investigators observed greater brain activations in the frontal regions associated with cognitive regulation of pain after CBT.
Repetitive multiple cranial nerve blocks may offer a clinically meaningful benefit as a preventative measure in patients with chronic migraine.
Researchers evaluated sensory function in the trigeminocervical region in patients with cluster headache, migraine headache, and tension-type headache.
A narrative review summarizes recent data on the pathophysiology, epidemiology, and burden of disease and treatment of menstrual migraine.
Youth with a history of status migranosus are more likely to experience an increase of >4 headache days per month during a follow-up evaluation.
Anti-calcitonin gene-related peptide monoclonal antibodies are the first approved pharmacologic treatments developed explicitly for the prevention of migraine.
Yoga plus medical care is better than medical therapy alone for the treatment of episodic migraines.
Study findings suggest that pain modulation may be impaired in patients with migraine in the headache-free interval, despite an unaffected sensory profile.
The FDA has approved an expanded indication for the gammaCore device to include prevention of migraine.
Undergoing 20 sessions of manual acupuncture is superior to sham acupuncture and usual care for prophylactic treatment in migraine.